5min chapter

Breakpoints cover image

#68 – IDWeek 2022 Recap: Late Breaking Trials and Pipeline Antibacterials

Breakpoints

CHAPTER

SCR 109 and C. Diff

SCR 109 was well tolerated through 24 weeks, and the most common side effects were mainly gastrointestinal. Ibiza is a small molecule guanazine analog that competitively inhibits the DNA pool 3C enzyme. It's different from SCR 109 in that it is a C. diff episode treatment product, not prevention for recurrence. The microbiome pearls at the end of these novel C. diff agents are always just so fascinating.

00:00

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode